SKYTROFA costs from around $3,120.00 to over $15,000.00 per carton, as it depends entirely on the prescribed dosage that is prescribed and the pharmacy.
Because SKYTROFA is a brand name biologic drug with no generic alternative, the retail cost of SKYTROFA without insurance is very high.
Although with health insurance and a Co-Pay Card you may pay as little as $5.00 per month for SKYTROFA.
If your commercial health insurance completely denies the coverage for SKYTROFA or excludes it, the manufacturer (Ascendis Pharma) does offer a Self Pay Program to lower the out of pocket burden.
SKYTROFA is often supplied in a carton that contains a 4 dose monthly supply and low doses (0.7 mg to 2.5 mg) the average discount price for SKYTROFA is around $3,271.00 per carton and for high doses of SKYTROFA, such as 11 mg to 13.3 mg, the average discounted price jumps up significantly and ranges from $11,970.00 to $14,470.00 or more per carton with retail prices also exceeding $15,000.00
SKYTROFA begins working and releasing active growth hormone in the body immediately after the first injection, although for any visible or measurable clinical results it takes several months to become apparent.
The SKYTROFA medication is a long acting prodrug that steadily releases somatropin over the course of the week following your one weekly injection.
And visible changes in height velocity or physical growth in children often take at least 3 months to 6 months of consistent treatment to measure.
Children on SKYTROFA in clinical studies grew an average of 4.4 inches over a 52 week or 1 year period.
In adults with growth hormone deficiency any improvements like reduced trunk fat and increased lean body mass are often evaluated around 38 weeks of treatment with SKYTROFA.
SKYTROFA also known as (lonapegsomatropin-tcgd) is a form of human growth hormone (hGH) replacement therapy.
The active ingredient in SKYTROFA is somatropin, which has the exact same molecular structure as the natural growth hormone the human body produces.
SKYTROFA is a long acting prodrug that is designed to slowly and steadily release unmodified somatropin into your body over the course of one week and SKYTROFA is prescribed for the treatment of growth hormone deficiency (GHD) in pediatric patients (aged 1 year and older weighing at least 11.5 kg / 26 lbs) and in adults.
And unlike traditional growth hormone treatments that require daily injections, SKYTROFA is given once a week as a subcutaneous injection using a dedicated auto-injector.
When injecting SKYTROFA, you inject SKYTROFA either into the stomach (abdomen), thighs or buttocks.
If injecting the SKYTROFA into the stomach, (abdomen) you should avoid the 2 inch area that is directly around the navel (belly button).
If injecting SKYTROFA into the thighs, you should inject SKYTROFA into the front or outer sides of the mid thigh.
And for the buttocks, SKYTROFA should be injected into the upper, outer quadrant.
When injecting SKYTROFA, rotate the sites by changing the injection site each week, and move to a slightly different spot within the same body area.
Doing this prevents the loss of thinning of fatty tissue under the skin also known as lipoatrophy.
Also never inject SKYTROFA through clothes and always clean the skin first with an alcohol wipe and allow it to dry.
Don't inject SKYTROFA into skin that is bruised, tender, red, hard, scarred, or irritated and press the SKYTROFA auto injector firmly against the clean skin for 10 to 15 seconds until the device beeps and a green check mark also appears.
The medication SKYTROFA is given or taken as a subcutaneous, under the skin injection one time per week and on the same day every week it's taken.
You can take your dosage of SKYTROFA 2 days before or 2 days after your scheduled dosing day of SKYTROFA if needed, as long as there are at least 5 days between the doses of SKYTROFA.
For missed doses, if you forget a dose of SKYTROFA, give it as soon as possible within 2 days or 48 hours of the missed day.
And if more than 2 days have passed, you should skip that dose of SKYTROFA and then resume your regular weekly schedule of SKYTROFA on your normal day.
SKYTROFA is used for the replacement of endogenous growth hormone in adults with GHD (as well as in pediatric patients aged 1 year and older who weigh at least 11.5 kg / 26 lbs).
SKYTROFA is a once weekly subcutaneous injection delivered via a dedicated auto-injector.
The FDA expanded the label to include adult GHD on July 28, 2025, following the Phase 3 foresiGHt clinical trial.
The side effects of SKYTROFA include viral infections, fever (pyrexia), cough, nausea and vomiting, diarrhea, stomach (abdominal) area pain, bleeding (hemorrhage), joint pain (arthralgia), and arthritis, as well as mild injection-site reactions in children.
And in adults the side effects of SKYTROFA include swelling due to fluid build-up (edema) and low thyroid hormone levels (hypothyroidism), along with joint pain, numbness, and dizziness.
Serious side effects of SKYTROFA include fluid retention, high blood sugar and diabetes, decreased hormone levels, intracranial hypertension, bone and spine issues in children, pancreatitis, tumor growth risk, severe allergic reactions and infection site tissue changes.
Fluid retention involves excess fluid in the body causing swelling in the hands and feet, joint or muscle pain, or carpal tunnel symptoms (burning or tingling).
High blood sugar and diabetes involve new or worsening high blood sugar levels or diabetes.
Decreased hormone levels involve drops in cortisol, (which causes extreme fatigue, dizziness, weakness, or skin darkening) or even drops in thyroid hormone.
Intracranial hypertension involves increased pressure inside your brain, leading to headaches, vision changes, or nausea.
Bone and spine issues in children involve slipped capital femoral epiphysis (hip or knee pain, or a limp that can lead to bone tissue damage/osteonecrosis) and the progression of scoliosis (curvening of the spine).
Pancreatitis involves severe and constant stomach pain, which can also be a sign of inflammation of the pancreas.
Tumor growth risk, involves increased risk of growth of an existing tumor/cancer or recurrence in pediatric brain/head radiation survivors.
Severe allergic reactions involve face, mouth, tongue, or throat swelling or difficulty breathing.
And injection site tissue changes include loss of fat or tissue weakness at the injection site which is minimized by rotating the injection spots.